Compare Illumina, Inc. (ILMN) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Orion Office REIT Inc — how do they compare? Illumina, Inc. trades at $190.08 (market cap $27.94B), while Orion Office REIT Inc trades at $2.68 (market cap $150.60M). The key difference: Illumina, Inc. is far larger — about 185.5× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.02% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | ONL | |
|---|---|---|
Market Cap | $27.94B | $150.60M |
Sector | Health | Real Estate |
52-Week High | $194.33 | $3.04 |
52-Week Low | $91.00 | $1.93 |
Enterprise Value | $29.33B | $634.25M |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
ONL trades at $2.65, up 0.76% today, with a bullish technical signal despite bearish moving averages. The company reported Q1 2026 earnings with a net loss of $0.24 per share, missing estimates, while revenue declined to $147.65 million in 2025. A strategic review is underway with Wells Fargo and JPMorgan, focusing on portfolio repositioning and debt management, as highlighted in recent earnings calls (MarketBeat, 2026-05-14).
Outlook remains challenging due to persistent losses and high leverage, but the strategic shift toward dedicated-use assets and resolved refinancing risks offer potential upside. Investors face significant execution and market headwinds, with analyst consensus split evenly between Buy and Hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
